Navigation Links
Kosan in Medical Technology

Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial

... HAYWARD, Calif., June 3 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) today an...emedications and ease of pharmacist preparation. kosan anticipates conducting additional studies with tan...s trastuzumab will continue on study per protocol. kosan does not plan to enroll additional patients in thi...

Kosan Announces Data Presentations at ASCO 2008 Annual Meeting

... HAYWARD, Calif., May 14 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) today an...of the University of Pennsylvania. About Kosan kosan Biosciences is a biotechnology company advancing t... in a Phase 1 trial. For additional information on kosan Biosciences, please visit the company's website at...

Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR

...AYWARD, Calif., April 16 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) presente...all of the leukemia models tested. About Kosan kosan Biosciences is a biotechnology company advancing t... in a Phase 1 trial. For additional information on kosan Biosciences, please visit the company's website at...

Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer

...AYWARD, Calif., April 14 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) today an...disease in many additional tumors. About Kosan kosan Biosciences is a biotechnology company advancing t... in a Phase 1 trial. For additional information on kosan Biosciences, please visit the company's website at...

Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer

...HAYWARD, Calif., Jan. 15 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) today an...t cancer represents a major market opportunity for kosan that we intend to pursue," said Robert G. Johnson,...hree weeks out of four weeks in repeated cycles. kosan is also testing alvespimycin delivered orally in a...

Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash

... HAYWARD, Calif., Dec. 8 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) presente...d to be progression-free survival. About Kosan kosan Biosciences is a biotechnology company advancing t...heat shock protein 90) inhibitors and epothilones. kosan is leveraging its proprietary discovery platform t...

Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting

...HAYWARD, Calif., Oct. 23 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) presente...pending on data from expanded dose cohorts. About kosan kosan Biosciences is a biotechnology company advancing t...

Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial

...AYWARD, Calif., Sept. 10 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) presente...with reduced doses (one patient remains on study). kosan plans to continue to enroll patients at the 80 mg/...tion. Expanded Phase 1 Trial Includes Paclitaxel kosan has expanded the Phase 1 trial to add weekly dosin...

Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma

...HAYWARD, Calif., Sept. 6 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) today an...e FDA's Special Protocol Assessment (SPA) process, kosan and the FDA have reached agreement on overall prot...-agent bortezomib. The Special Protocol Assessment kosan has completed applies to the TIME-1 trial. TIME-2,...

Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma

... HAYWARD, Calif., Aug. 2 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) today an...ed primarily by the patient's level of M protein. kosan anticipates that the pivotal TIME-1 trial will beg...ion of cytotoxic proteins, leading to cell death. kosan reported data from a Phase 1b trial of tanespimyci...

Kosan's Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease

... HAYWARD, Calif., Aug. 6 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) today an...PF-04548043 in healthy subjects. In December 2006, kosan and Pfizer established a worldwide license agreeme... and this may improve the symptoms of GERD. About kosan ...

Kosan Announces Data Presentations at Upcoming AACR Annual Meeting

...cer therapeutics kosan Biosciences is a biotechnology company advancing t...heat shock protein 90) inhibitors and epothilones. kosan is leveraging its proprietary discovery platform t...ization agreement. For additional information on kosan Biosciences, please visit the company's website at...

Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR

...erval can lead to ventricular arrhythmia). About kosan kosan Biosciences is a biotechnology company advancing t...heat shock protein 90) inhibitors and epothilones. kosan is leveraging its proprietary discovery platform t...

Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR

...ent and duration of tumor regression was curative. kosan is currently advancing KOS-1803 through later-stag...nt in the area of cancer. In early 2007, Roche and kosan announced the decision to advance KOS-1584 into Ph...rch (AACR), being held in Los Angeles, CA. About kosan ...

Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR

...durability of action and a wide therapeutic index. kosan anticipates becoming the first company to advance ...r into clinical development. "We believe that kosan has established an industry-leading position in NE...ent potentially novel anticancer agents. About kosan ...

Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO

...s (with continued BRAF mutation analysis). About kosan kosan Biosciences is a biotechnology company advancing t...heat shock protein 90) inhibitors and epothilones. kosan is leveraging its proprietary discovery platform t...

Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO

...nd patients treated with bortezomib alone. About kosan kosan Biosciences is a biotechnology company advancing t...heat shock protein 90) inhibitors and epothilones. kosan is leveraging its proprietary discovery platform t...

Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO

...-small cell lung cancers and sarcomas. Roche and kosan plan to advance KOS-1584/R1645 into Phase 2 trials...ty with established chemotherapy regimens. About kosan kosan Biosciences is a biotechnology company advancing t...

Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO

...ans to add paclitaxel (Taxol(R)) to the regimen. kosan plans to initiate a Phase 2 study of alvespimycin ...b. This trial will be conducted in Eastern Europe. kosan anticipates that regulatory filings to support ini...clinical trial will be completed by mid-year 2007. kosan plans to initiate a larger, international Phase 2/...
Other Tags
(Date:7/10/2014)... 10 July 2014 Amyloid diseases, such as ... spongiform encephalopathies, all share the common trait that ... plaques. Yet in vitro studies have found that ... themselves are very toxic. New evidence using two-dimensional ... structure during the amylin aggregation pathway that may ...
(Date:7/10/2014)... 10,2014 For children and teens living with a ... contribute to decreased quality of life, reports a study ... Behavioral Pediatrics , the official journal of the ... The journal is published by Lippincott Williams & ... . , "Self-competence may function as a protective factor ...
(Date:7/10/2014)... natural-color satellite image was collected by the Moderate Resolution ... 10, 2014. Each hot spot, which appears as a ... on the MODIS instrument recognized temperatures higher than background. ... image, such hot spots are diagnostic for fire. ... little danger coming directly from the fires, although the ...
Breaking Biology News(10 mins):New technology reveals insights into mechanisms underlying amyloid diseases 2For children with pacemakers, 'self-competence' affects quality of life 2
(Date:7/10/2014)... of Health and Human Services (HHS) has announced a ... Seidman Cancer Center totaling $4.7 million to support a ... with complex cancer. , Titled "Evidence-Conformant Oncology Care," ... UH to enhance care for adult cancer patients with ... health care utilization. , "We believe that ...
(Date:7/10/2014)... The benefits of medical imaging far outweigh the ... Right Way, with The Right Radiation Dose. However, overuse ... Mayo Clinic is leading a collaborative effort to ensure ... published online in the Journal of Patient Safety ... Joint Commission, the Intersociety Accreditation Commission, and the Centers ...
(Date:7/10/2014)... (July 10, 2014) A research review identifying the ... important first step in the process of developing evidence-based ... a new report published by Neurosurgery ... Neurological Surgeons . The journal is published by ... Wolters Kluwer Health . , Based on ...
(Date:7/10/2014)... Depressed men with localized prostate cancer were more ... cancer, received less effective treatments and survived for ... not depressed, a UCLA study has found. , ... several factors such as bias against the mentally ... depressed man,s lack of investment in his general ...
(Date:7/10/2014)... prove useful in treating small cell lung cancer - the ... Cancer Research UK Manchester Institute, based at The University of ... up with experts at AstraZeneca, as part of a collaboration ... AZD3965 - on small cell lung cancer cells. , The ... also helps identify which patients are most likely to respond ...
Breaking Medicine News(10 mins):Health News:UH Case Medical Center awarded $4.7 million grant from HHS 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 3Health News:Mayo Clinic calls for standardization of safe imaging protocols for children 2Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3Health News:Depressed men with prostate cancer are diagnosed later stage, get less effective therapies 2Health News:New drug active against most aggressive type of lung cancer cells 2
Other Contents